Table 2 Rate of patients with preoperative elevated tumor marker CA19-9.
From: Tumor markers as a diagnostic key for hilar cholangiocarcinoma
Variable | Group a (CA19-9 ≤ 1000 U/ml) | Group B (CA19-9 > 1000 U/ml) | p-value |
|---|---|---|---|
N = | 111 | 25 | |
CA19-9 (U/ml) | 208 ± 247 | 3864 ± 2999 | 0.00002 |
(Mean/±) | |||
CA19-9 (U/ml) | 119 (0.3-1000) | 2960 (1009-13500) | |
(Median/range) | |||
Mean survival | 23 ± 25 | 12 ± 22 | > 0.05 |
(Months/±) | |||
Median survival | 13 (3 to 38) | 8 (1 to 9) | |
(Months/IQR) | |||
Nonresectable | 27 (30%) | 16 (64%) | 0.0006 |